Unique, Fluorescent Nanocrystal Technology to Combat $1 Trillion in Annual Losses by Global Manufacturers Carlsbad and San Francisco, Calif., — March 23, 2009 — Life Technologies Corporation (NASDAQ: LIFE), and Nanosys, Inc. today announced a cross-licensing agreement to share rights to an intellectual property estate related to fluorescent nanocrystals (also known as quantum dots). New products developed as a result of this agreement will help prevent counterfeiting worldwide. The quantum dots will allow manufacturers to trace the source of their materials and manage and track product shipments, helping stop counterfeit material use in pharmaceutical and diagnostic products, food and beverages (and their agricultural and environmental sources), and electronic goods, reducing counterfeiting of currency, documents, fine art, and luxury goods.

Quantum dots are tiny (nanometer size) fluorescent particles. While invisible to the eye, they emit intensely bright light when exposed to low-cost violet or ultraviolet light sources. Quantum dots display unique colors due to differences in size. Due to their particulate nature, quantum dots can easily be blended with polymers, gels, or inks and printed onto most surfaces. The complexity of their manufacturing process also makes them almost impossible to counterfeit. And, because quantum dots are highly stable, extremely bright and absorptive, they offer advancements in solid state lighting, solar collector and electronic display technology.

Life_clip_image001
Life_clip_image001

Quantum dots glow when exposed to an ultraviolet light source. The color of the light depends upon the size of the quantum dot.

“Life Technologies’ quantum dots are currently being used in life science research and pathology, but there are vast opportunities to use them in a wide variety of applications,” said Paul Grossman, Senior Vice President of Corporate Development & Strategy at Life Technologies. “Our new partnership with Nanosys will allow both companies to expand the opportunities for our combined technologies, and further the reach of Life Technologies into the applied markets.”

Jason Hartlove, CEO of Nanosys, continued “We are very excited to be partnering with Life Technologies to use our combined nanotechnology to address the growing and pervasive problem of counterfeit goods. By working together with Life Technologies, we can now offer comprehensive solutions and technology licensing to our customers to help them use our unique quantum dot materials for anti-counterfeiting.”

The combination of the two companies’ vast intellectual property estates includes over 270 patents and applications, including 84 issued U.S. patents, for use of fluorescent nanocrystals. The licenses will allow both Life Technologies and Nanosys to work with a variety of manufacturers who want to protect their products from counterfeiting. Nanosys is currently using quantum dot technology to produce devices such as LEDs, photovoltaics and electronic displays, while Life Technologies is focused on life science applications, including in vitro and in vivo cell imaging, flow cytometry, tumor margin detection, and protein detection.

The worldwide counterfeit goods trade, excluding counterfeit money, is believed to be on the order of $1 trillion annually. The U.N. estimates counterfeit drug sales alone were over $300 billion in 2008, while the World Customs Organization believes that other counterfeit goods sold for more than $600 billion. According to U.S. Immigration and Customs Enforcement, these losses cost American industry and trade between $200 billion and $250 billion each year and equate to 750,000 American jobs lost.

About Life Technologies

Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website:www.lifetechnologies.com.

About Nanosys, Inc.

Nanosys, Inc. is a leader in the development of nanotechnology enabled products utilizing high performance inorganic nanostructures. Nanosys has built one of the broadest technology platforms in the industry with over 650 patents and patent applications covering fundamental areas of nanotechnology. Based in Palo Alto , California and privately held, Nanosys collaborates with industry leaders to develop revolutionary high-value, high-performance products for life sciences, computing, optoelectronics, renewable energy, and defense. Additional information on Nanosys can be found at www.nanosysinc.com.

Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.